Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Patients aged between 18 and 65 years.
Caucasian ethnicity.
Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
Have at least one year of history of migraine.
Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
Neurological focus in the examination.
Pregnancy or breastfeeding period.
Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.